A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database

A Nationwide Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the DANBIO Register

The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish Database for Biologic Therapies (DANBIO).

Inclusion Criteria:

• Diagnosis of rheumatoid arthritis (RA) or psoriatic arthritis (PsA)
• Receiving treatment with abatacept
• Receiving treatment with non-targeted DMARD
• Receiving treatment with targeted DMARD

Exclusion Criteria:

-Not applicable